Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Keros Therapeutics Inc stock

Learn how to easily invest in Keros Therapeutics Inc stock.

Keros Therapeutics Inc is a biotechnology business based in the US. Keros Therapeutics Inc shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Keros Therapeutics Inc employs 75 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Keros Therapeutics Inc

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KROS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Keros Therapeutics Inc stock price (NASDAQ: KROS)

Use our graph to track the performance of KROS stocks over time.

Keros Therapeutics Inc shares at a glance

Information last updated 2022-06-25.
Latest market close$26.03
52-week range$24.38 - $68.29
50-day moving average $42.06
200-day moving average $47.63
Wall St. target price$93.75
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.85

Buy Keros Therapeutics Inc shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
$0
$0
N/A
Financial advice powered by relationships, not commissions.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Keros Therapeutics Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Keros Therapeutics Inc price performance over time

Historical closes compared with the close of $26.03 from 2022-06-28

1 week (2022-06-22) -1.55%
1 month (2022-05-27) -25.95%
3 months (2022-03-30) -51.49%
6 months (2021-12-30) -53.77%
1 year (2021-06-30) -38.71%
2 years (2020-06-30) -30.61%
3 years (2019-06-26) N/A
5 years (2017-06-26) N/A

Keros Therapeutics Inc financials

Revenue TTM $20.1 million
Gross profit TTM $-35,043,000
Return on assets TTM -16.42%
Return on equity TTM -28.42%
Profit margin 0%
Book value $9.31
Market capitalisation $686.4 million

TTM: trailing 12 months

Keros Therapeutics Inc share dividends

We're not expecting Keros Therapeutics Inc to pay a dividend over the next 12 months.

Keros Therapeutics Inc share price volatility

Over the last 12 months, Keros Therapeutics Inc's shares have ranged in value from as little as $24.38 up to $68.29. A popular way to gauge a stock's volatility is its "beta".

KROS.US volatility(beta: 1.22)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Keros Therapeutics Inc's is 1.2249. This would suggest that Keros Therapeutics Inc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Keros Therapeutics Inc overview

Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. .

Frequently asked questions

What percentage of Keros Therapeutics Inc is owned by insiders or institutions?
Currently 11.457% of Keros Therapeutics Inc shares are held by insiders and 89.383% by institutions.
How many people work for Keros Therapeutics Inc?
Latest data suggests 75 work at Keros Therapeutics Inc.
When does the fiscal year end for Keros Therapeutics Inc?
Keros Therapeutics Inc's fiscal year ends in December.
Where is Keros Therapeutics Inc based?
Keros Therapeutics Inc's address is: 99 Hayden Avenue, Lexington, MA, United States, 02421
What is Keros Therapeutics Inc's ISIN number?
Keros Therapeutics Inc's international securities identification number is: US4923271013
What is Keros Therapeutics Inc's CUSIP number?
Keros Therapeutics Inc's Committee on Uniform Securities Identification Procedures number is: 492327101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site